slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
212,851-212,880 of 319,975
24
The slide features a 3D molecular model and a UI overlay displaying various pharmacological parameters (potency, selectivity, stability, etc.) and a merit score.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
25
The chart illustrates a Pareto frontier where the AI selects compounds that are not necessarily the highest in potency but provide high information gain.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
26
The slide uses a series of dose-response curves to demonstrate differential drug sensitivity across patient samples.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
27
Exscientia | Investor Presentation Deck | 75 slidesExscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
28
Exscientia | Investor Presentation Deck | 75 slidesExscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
29
The visual depicts a molecular structure, likely representing the drug candidate or its target.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
30
MTD = Maximum Tolerated Dose; ORR = Objective Response Rate; ABS = Adenosine Burden Score.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations Beat · Visualization1 hit
31
The slide uses a human anatomy diagram to map patient counts to specific disease locations.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations Beat · Visualization1 hit
32
The slide shows a heatmap of 43 patient samples across different cancer types, correlating ABS with signature scores.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
33
The slide presents two distinct sets of data: a comparative line chart (left) and a series of box-and-whisker plots (right) showing performance across different cell types.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
34
The slide uses a combination of bar charts and scatter plots to demonstrate the inverse relationship between ABS and TIS.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
35
The slide presents two line/box plots showing dose-dependent responses to stabilised adenosine.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
36
The slide presents two key clinical data plots: a pharmacodynamic correlation (exposure vs inhibition) and a pharmacokinetic profile (concentration over time).Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
37
The slide features a 3D molecular visualization of the inhibitor.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
38
The slide outlines a standard oncology clinical trial design (Dose Escalation to RP2D to Dose Expansion).Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
39
The slide uses a human anatomy diagram to map specific cancer types to their respective incidence numbers.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
40
Includes a biological pathway diagram and a honeycomb-style indication map.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
41
The slide uses a three-column layout to define the target product profile (TPP) requirements for a drug candidate.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
42
The table uses a color-coded system (green/yellow/red) to indicate performance against criteria.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
43
Data source: Besnard et al, AACR (2022).Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
44
The waterfall plot shows drug response scores across many samples, indicating sensitivity. The right side summarizes findings and the rationale for combination testing.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
45
The slide uses a heatmap to display binary synergy results (Yes/No) across three drug combinations, alongside a bar chart showing single-agent sensitivity.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
46
The slide uses a Venn diagram to illustrate the overlap of gene modulation between peripheral blood and primary tumours, and line charts to show dose-response curves for two specific biomarkers.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
47
The slide features a 3D molecular visualization of the protein target.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
48
TPP stands for Target Product Profile.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
49
The slide uses a traffic-light color coding system to highlight performance against criteria.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
50
The slide uses a process-flow layout to describe the company's R&D methodology.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
51
The visual background is a stylized molecular structure, emphasizing the biotech/pharma context.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
52
Exscientia | Investor Presentation Deck | 75 slidesExscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit
53
Includes two scientific diagrams illustrating the mechanism of action and brain penetration.Exscientia | Investor Presentation Deck | 75 slides · Exscientia
Pitch deck Investor relations 1 hit